Literature DB >> 208034

Replacement estrogen therapy for menopausal vasomotor flushes. Comparison of quinestrol and conjugated estrogens.

S B Baumgardner, H Condrea, T A Daane, J H Dorsey, H N Jurow, J P Shively, M Wachsman, L R Wharton, M J Zibel.   

Abstract

Quinestrol, conjugated estrogens, or placebo was used to treat 156 patients with pernicious vasomotor instability in a prospective, double-blind, randomized, multiinvestigator trial. Vasomotor flushes were severe in approximately 80% of the cases and moderate in 20%, relatively equally distributed among the various drug groups. Both qinestrol and conjugated estrogens were significantly more effective than placebo in relieving vasomotor symptoms (by chi2 analysis, P less than or equal to 0.05). Greatest improvement was seen in the group receiving the higher once weekly quinestrol dosage of 0.2 mg followed by the group on the lower quinestrol dosage of 0.1 mg once weekly and the group on conjugated estrogens, 1.25 mg daily for 21 days on and 7 days off. No significant difference in relief of vasomotor flushes was shown between the active drug groups. No drug-related complications or side reactions of significance occurred. The results indicate that once weekly quinestrol is effective in relieving the vasomotor symptoms of the menopause. Either of two once weekly quinestrol regimens is an effective as conjugated estrogens given daily in a cyclic manner and therefore offers an alternative form of exogenous estrogen therapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 208034     DOI: 10.1097/00006250-197804000-00013

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

Review 1.  Current status of postmenopausal oestrogen therapy.

Authors:  R L Young; J W Goldzieher
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

2.  Reduction of menopausal hot flushes by methyldopa. A double blind crossover trial.

Authors:  B I Nesheim; T Saetre
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 3.  Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.

Authors:  A H Maclennan; J L Broadbent; S Lester; V Moore
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.